Cystic fibrosis

Cystic fibrosis is a life-threatening genetic disorder that primarily affects the lungs and digestive system. It is caused by a defective gene that leads to the production of thick, sticky mucus that clogs the airways and various organs. As a result, individuals with cystic fibrosis face a range of challenges, including difficulty breathing, recurring lung infections, and malnutrition. Despite advances in treatment, cystic fibrosis remains a serious condition that requires ongoing management and care.

What is Cystic fibrosis?

Cystic fibrosis, also known as mucoviscidosis, is an inherited disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is responsible for regulating the movement of salt and water in and out of cells. When the CFTR gene is defective, it leads to the production of abnormally thick and sticky mucus that accumulates in the lungs, pancreas, and other organs. This mucus buildup disrupts normal function and leads to a range of symptoms and complications. Although cystic fibrosis is a progressive condition, advances in treatment have greatly improved the outlook for those affected.

The symptoms of cystic fibrosis can vary in severity and may change over time. Some common symptoms include:

1. Respiratory symptoms

• Persistent cough that produces thick mucus

• Wheezing and shortness of breath

• Recurring lung infections and inflammation

• Chronic sinusitis and nasal congestion

2. Digestive symptoms

• Diarrhoea and malnutrition

• Poor growth and weight loss

• Blockage of the intestine (meconium ileus) in newborns

• Pancreatitis and cystic fibrosis-related diabetes mellitus (CFRDM) in adults

3. Other symptoms

• Saltiness of sweat (parents may notice a salty taste when kissing their child)

• Infertility in men owing to congenital bilateral absence of the vas deferens (CBAVD)

• Complications in pregnancy for women with cystic fibrosis

The stages of cystic fibrosis can be broadly categorised as follows:

• Newborns may present with meconium ileus, respiratory distress, and failure to thrive.

• Children often experience recurring lung infections, digestive problems, and poor growth.

• Adults with cystic fibrosis may face additional challenges, such as the development of diabetes, osteoporosis, and liver disease.

Cystic fibrosis primarily affects the lungs and digestive system. The primary cause of cystic fibrosis is a mutation in the CFTR gene, which is responsible for regulating the movement of salt and water in and out of cells.

• Inheritance pattern: Cystic fibrosis is an autosomal recessive disorder, meaning an individual must inherit one copy of the mutated gene from each parent to develop the condition.

• CFTR gene mutation: The CFTR gene mutation leads to the production of thick, sticky mucus that accumulates in various organs, particularly the lungs and pancreas.

Other factors that may influence the development and severity of cystic fibrosis include:

• Ethnicity: Cystic fibrosis is more common among individuals of Northern European descent, although it can affect people of any race or ethnicity.

• Environmental factors: Exposure to certain environmental triggers, such as cigarette smoke or air pollution, may exacerbate cystic fibrosis symptoms.

Several factors can increase the risk of developing cystic fibrosis.

1. Genetic Factors

• Cystic fibrosis is caused by a mutation in the CFTR gene. To develop cystic fibrosis, an individual must inherit two abnormal copies of this gene, one from each parent.
• Carriers who have one abnormal copy of the CFTR gene do not have cystic fibrosis symptoms themselves, but they can pass the faulty gene on to their children. If both parents are carriers, each pregnancy has a 25% chance of the child having CF.
• Modern diagnostic testing increasingly uses expanded CFTR variant panels or full gene sequencing because hundreds of pathogenic variants exist, and panels limited to F508del under-detect cases in individuals of non-European ancestry. The CFTR2 database provides updated information on variant pathogenicity and supports more equitable diagnostic approaches according to the CFF Patient Registry (2023).

2. Family History

• Having a family history of cystic fibrosis significantly raises the risk, especially if one or both biological parents either have cystic fibrosis themselves or are carriers of the abnormal gene.

3. Ethnicity

• Cystic fibrosis is most prevalent in people of Northern European descent, particularly Caucasians. The condition is less common in Hispanic, African American, and Asian American populations.

4. Age of Diagnosis

• While cystic fibrosis is usually diagnosed in early childhood, with over 75% of cases identified by age 2, some milder cases may not present until adulthood.

Cystic fibrosis can cause a range of complications, particularly as the condition progresses. Some of the main areas affected include:

1. Respiratory System

• Recurring lung infections are common in cystic fibrosis because of the thick, sticky mucus that traps bacteria. Over time, repeated infections can damage the lungs.
• Cystic fibrosis can cause bronchiectasis, a chronic condition where the airways become abnormally widened and scarred, further increasing infection risk.
• Pneumothorax, or collapsed lung, may occur in advanced cystic fibrosis. This happens when damaged lung tissue ruptures, allowing air to leak into the chest cavity.

2. Digestive System

• Mucus can block ducts in the pancreas, preventing digestive enzymes from reaching the intestines. This leads to malnutrition and poor growth.
• Patients with cystic fibrosis have an increased risk of diabetes, gallstones, and liver disease owing to mucus buildup affecting organ function(Lopez et al., 2023).

3. Reproductive System

• Most males with cystic fibrosis are infertile due to congenital bilateral absence of the vas deferens (CBAVD). Testicular function is typically preserved, meaning they produce sperm and can father biological children through assisted reproductive techniques such as sperm retrieval with IVF or ICSI. Females with CF may have reduced fertility due to thick cervical mucus and nutritional or pulmonary factors, but can often conceive with appropriate care (Lopez et al., 2023).

4. Others

• Modern diagnostic testing increasingly uses expanded CFTR variant panels or full gene sequencing because hundreds of pathogenic variants exist, and panels limited to F508del under-detect cases in individuals of non-European ancestry. The CFTR2 database provides updated information on variant pathogenicity and supports more equitable diagnostic approaches.

s cystic fibrosis arises from genetic causes, prevention efforts are primarily centred around genetic counselling and testing.

1. Genetic Testing

• Genetic tests can screen for mutations in the CFTR gene to identify cystic fibrosis carriers. Testing is especially useful for those with a family history of cystic fibrosis or couples planning a pregnancy.
• These carrier tests analyse DNA from a blood, saliva, or cheek cell sample to detect abnormalities in the cystic fibrosis gene.
• Prevention efforts include genetic counselling and carrier testing. Expanded carrier screening panels improve detection of diverse CFTR variants. Preimplantation genetic testing (PGT) is an option for carrier couples undergoing IVF. Newborn screening programs also play a critical preventive role by ensuring early diagnosis and initiation of appropriate management.

2. Pre-Conception Genetic Counselling

• Couples who are cystic fibrosis carriers can seek genetic counselling before conceiving. This allows them to understand their risks and make informed choices about starting a family.

3. Prenatal Testing Options

• For at-risk pregnancies, prenatal tests such as amniocentesis or chorionic villus sampling can determine if the fetus has inherited cystic fibrosis.

4. Lowering Environmental Risks

• While not directly preventing mucoviscidosis, avoiding smoking and secondhand smoke exposure can help manage cystic fibrosis symptoms if present.
• Maintaining overall health through proper nutrition and exercise is also beneficial.

Early diagnosis is crucial for the effective management and treatment of cystic fibrosis. There are several diagnostic tests available to confirm the presence of the condition.

• Newborn screening: According to the CFF Patient Registry (2023), newborn screening typically uses an elevated immunoreactive trypsinogen (IRT) level followed by CFTR variant testing; however, algorithms vary between countries and regions.
• Sweat test: The sweat test is considered the gold standard for diagnosing cystic fibrosis. It measures the amount of salt in a person's sweat, as individuals with cystic fibrosis have higher levels of salt in their sweat. According to the CFF Patient Registry (2023), a sweat chloride level ≥60 mmol/L is diagnostic for cystic fibrosis, while values between 30–59 mmol/L are considered intermediate depending on age and clinical context. Levels <30 mmol/L make cystic fibrosis unlikely.
• Genetic testing: Genetic tests can identify specific mutations in the CFTR gene, confirming the diagnosis of cystic fibrosis and helping to determine the severity of the condition.

In addition to these tests, a comprehensive evaluation by a multidisciplinary team at a specialised cystic fibrosis care centre is essential for an accurate diagnosis and the development of an individualised treatment plan. This evaluation may include a thorough medical history, physical examination, and additional tests to assess the function of various organs affected by cystic fibrosis.

Cystic fibrosis (CF) requires a comprehensive, lifelong treatment strategy focused on maintaining lung function, managing digestive issues, and preventing complications.

• Respiratory Therapy:

Airway clearance techniques like chest physiotherapy, postural drainage, and the use of devices such as oscillatory vests help remove thick mucus from the lungs. Inhaled medications are also key components:

1. Salbutamol: A short-acting bronchodilator that relaxes the airway muscles, improving airflow and easing breathing in cystic fibrosis patients.
2. Dornase alfa, hypertonic saline, and airway clearance techniques are evidence-based components of CF respiratory management and significantly improve mucus clearance and lung function (Xu et al., 2023).
3. Tobramycin inhalation solution or powder is used for chronic suppression of Pseudomonas aeruginosa in cystic fibrosis (Xu et al., 2023).
4. Aztreonam lysine for inhalation is indicated for chronic Pseudomonas infections and helps reduce exacerbations.

• CFTR modulators (such as ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor) target the underlying defect in the CFTR gene, improving chloride transport and significantly enhancing lung function, nutritional status, and overall quality of life in eligible patients (Xu et al., 2023).
• Anti-inflammatory Medications:

1. High-dose ibuprofen may slow lung-function decline in selected pediatric patients, but requires careful monitoring due to gastrointestinal and renal risks.

2. Chronic azithromycin therapy is used for its anti-inflammatory and immunomodulatory effects, particularly in patients chronically infected with Pseudomonas aeruginosa.

    

• Nutritional Support:

A high-calorie, high-fat diet supports energy needs. Pancreatic enzyme replacement therapy (pancrelipase) is essential for digestion and nutrient absorption. Fat-soluble vitamin supplements (A, D, E, and K) are also routinely prescribed.

• Other Medications:

1. Insulin may be required if cystic fibrosis-related diabetes develops.
2. Proton pump inhibitors (e.g., omeprazole) may be used to enhance enzyme function and manage reflux.

Management of CF is guided by a multidisciplinary team, and treatment plans are tailored to the individual's symptoms, genotype, and age. Regular monitoring and early intervention are crucial to improving outcomes and extending life expectancy.

Living with cystic fibrosis requires a comprehensive and ongoing management plan to mitigate the symptoms and complications of this genetic disorder. While there is no cure for cystic fibrosis, a combination of daily management techniques, medications, and lifestyle adjustments can significantly improve quality of life.

1. Daily Management

Proper nutrition is crucial for individuals with cystic fibrosis. A high-calorie, high-fat diet helps maintain weight and support growth. Pancreatic enzyme supplements and vitamins are often necessary to aid digestion and ensure adequate nutrient absorption. Regular physical activity is also essential for overall health and to help clear mucus from the lungs. Exercise and pulmonary rehabilitation can be particularly beneficial in managing cystic fibrosis symptoms.

2. Medications and Therapies

Airway clearance therapy is a cornerstone of cystic fibrosis treatment. Techniques such as chest physical therapy, inhalers, and nebulisers help loosen and clear the thick, sticky mucus that characterises mucoviscidosis. Antibiotics and anti-inflammatory medicines are frequently used to treat and prevent lung infections, which are common in cystic fibrosis owing to the buildup of mucus in the airways.

3. Lifestyle Adjustments

To minimise the risk of infections, people with cystic fibrosis should avoid close contact with others who are sick and practice diligent hand hygiene. Stress management techniques, such as relaxation exercises, can help with improving overall well-being and coping with the emotional challenges of living with a chronic condition.

4. Social and Emotional Support

Joining support groups, either online or in-person, can provide invaluable connections and resources for individuals with cystic fibrosis and their families. Organizations specifically working with cystic fibrosis specialists can also assist in navigating insurance, legal, and financial issues related to living with cystic fibrosis.

Managing cystic fibrosis involves regular monitoring and prompt medical intervention when necessary. Knowing when to call the doctor is essential for preventing complications and maintaining optimal health.

1. Signs of Infection

Fever is often an indicator of infection in individuals with cystic fibrosis. If you develop a fever, it is crucial to notify your doctor immediately. Similarly, any changes in cough or sputum production, particularly if the mucus becomes thicker or more discoloured, should be reported promptly.

2. Respiratory Complications

Shortness of breath or difficulty breathing are red flags that require immediate medical attention. These symptoms may indicate a worsening of cystic fibrosis-related lung disease or the development of a serious complication. Chest pain or signs of a collapsed lung (pneumothorax) are medical emergencies that necessitate urgent care.

3. Gastrointestinal Issues

Severe abdominal pain or vomiting may signal a gastrointestinal blockage or other intestinal complication of cystic fibrosis. If you experience these symptoms, seek medical advice without delay.

• Cystic fibrosis, or mucoviscidosis, is a complex genetic disorder that affects multiple organ systems. While the symptoms and severity of cystic fibrosis vary from person to person, understanding the key aspects of this condition is essential for effective management.

• Cystic fibrosis is caused by mutations in the CFTR gene, which lead to the production of thick, sticky mucus that accumulates in the lungs, digestive system, and other organs. Common symptoms include persistent coughing, frequent lung infections, difficulty breathing, poor growth and weight gain, and digestive problems.

• Although there is no cure for cystic fibrosis, a multi-faceted treatment approach can significantly improve outcomes and quality of life. This includes daily airway clearance techniques, medications to manage infections and reduce inflammation, nutritional support, and lifestyle modifications to prevent complications.

• Early diagnosis through newborn screening and prompt initiation of treatment are critical for optimising health outcomes in individuals with cystic fibrosis. Regular follow-up with a multidisciplinary team experienced in cystic fibrosis care is essential for monitoring disease progression, adjusting treatments, and addressing any complications that may arise.

• Significant progress has been made in understanding the genetic basis of cystic fibrosis and developing targeted therapies. Continued research efforts aim to identify new treatments, improve existing therapies, and ultimately find a cure for this life-limiting disorder.